As reported by Medical News Today, scientists at the Institute Cancer Research (ICR) have received an award from the Royal Society of Chemistry (RSC) for the discovery and clinical development of abiraterone, a prostate cancer treatment.
The development of this prostate cancer drug is of particular significance as it is one of only a hand full of drugs which have been found to extend the lives of men suffering with late-stage prostate cancer.
Abiraterone has recently received approval in the US for men suffering with metastatic prostate cancer whom were no longer responding to chemotherapy. European approval is also pending.
The RSC is the largest European organisation that focuses on advancing chemical sciences. Their President, David Phillips stated the award was given “in recognition of their exemplary teamwork and scientific innovation that took abiraterone from idea to successful multi-centre Phase III clinical trials for the treatment of prostate cancer.”
